BAROSTIM NEO Hypertension Pivotal Trial
← catalyst calendarSponsored by CVRx, Inc. (industry) · CVRX — their whole pipeline →.
Phase
Not applicable
Status
Suspended
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10actual
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Company resources only allows adequate oversight for one pivotal trial at a time
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2013-04-12 | not stated | When the study began enrolling |
| Primary completion | Mar 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2012-09-05 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Uncontrolled Hypertension
Intervention
- Device: BAROSTIM NEO System and Medical Management — also filed as Neo System
Primary outcome
what the primary-completion date above is the date OFTo assess long-term adverse events in subjects implanted with the BAROSTIM NEO System.
measured For the duration of the study, up to ten years.
Permalink · CVRX's whole pipeline · Catalyst calendar · Every registered study · What changed